Pharma Firms Urged To Push For Post-Brexit Regulatory Equivalence Deal
Executive Summary
A mutual recognition agreement between the UK and EU on equivalence of regulatory procedures and processes could provide pharmaceutical companies with some stability and continuity post-Brexit – and save them some money.
You may also be interested in...
Japan Issues Strong Warning Over Brexit
Uncertainty is bad for business and can deter investment, warns Japan in relation to eventual talks on the UK’s exit from the EU. Japan’s preferred Brexit outcome? For the UK to keep both EU law and the European Medicines Agency.
England’s Innovative Medicines Fund To Put Spotlight On Rare Disease Treatments
While the much-anticipated Innovative Medicines Fund is likely to benefit rare diseases in particular, other products must gain too.
ATMP Withdrawals Are Keeping EU Regulators Awake At Night
Europe is becoming less competitive in the advanced therapy space, something that is reflected in the number of EU ATMP marketing authorization withdrawals, speakers said at an event organized by the Alliance for Regenerative Medicine.